Insulin degludec/Liraglutide(Tonghua Dongbao Pharmaceutical)

德谷胰岛素/利拉鲁肽（通化东宝）

Report date: 2026/05/20 20:02:01

Base Information

Drug NameInsulin degludec/Liraglutide(Tonghua Dongbao Pharmaceutical)

Drug Alias Nameinsulinum degludecum/liraglutidum地谷胰岛素/利拉鲁肽GLP-1 and basal insulin combination地谷胰岛素/利拉糖肽insulina degludec/liraglutida +[9]

ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Protein drugs > Recombinant polypeptideBiologics > Biosimilar

Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsInsulin receptor agonists

TargetsGlucagon-like peptide 1 receptorInsulin receptor

Therapy Area/IndicationsDiabetes Mellitus, Type 2

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsYes

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesTonghua Dongbao Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesTonghua Dongbao Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsDiabetes Mellitus, Type 2

Inactive IndicationsN/A

Other Information

ATC CodeN/A